UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Del ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants John Menditto - VP, IR and Corporate Communications Dr. David Mazzo - President and Chief Executive Officer Dr. Kristen Buck - EVP, Research and Development and Chief Medical Officer James Nisco - VP, Finance and Treasury Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therapeut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications David Mazzo - CEO James Nisco - VP, Finance and Treasury Kristen Buck - EVP, Research and Development and Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Kemp Dolliver - Brookline Capital Markets Pete Enderlin - MAZ Partner Joe Pantginis - H.C. Wainwright Operator Welcome to the Lisata Therapeutics First Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delawar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) D ...

LISTHER ATAPEUTICS A Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer Corporate Presentation | February 23, 2023 Nasdaq: LSTA www.lisata.com Copyright ©2023 Lisata Therapeutics, Inc. All rights reserved. Forward-looking Statements Notice This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of histor ...

LISTHER ATAPEUTICS A Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer LD Micro Main Event XV| October 2022 Nasdaq: LSTA www.lisata.com Copyright ©2022 Lisata Therapeutics, Inc. All rights reserved. Forward-looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, i ...

caladrius Developing Innovative Therapies that Treat or Reverse Disease David J. Mazzo, PhD President & Chief Executive Officer M ay 5 , 2 0 22| N a s d a q : C L B S 2 Information regarding disclosures Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this com ...

Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Conference call begins today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and six months ended ...